PRESS RELEASES

PRESS RELEASES

July 21, 2014
Second Quarter total revenue expected to be in the range of $8.75 million to $8.85 million , an increase of approximately 6-7% over the same period last year. BELGRADE, Mont. , July 21, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of
July 1, 2014
BELGRADE, Mont. , July 1, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Robert (Bob) Di Silvio as President of the
May 6, 2014
Company reports record core recurring biologics revenues of $8.7 million BELGRADE, Mont. --(BUSINESS WIRE)--May 6, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported
May 1, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--May 1, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Melanie Head as Vice President of Sales. Ms.
April 21, 2014
Core recurring Biologics revenues up 20% from prior year First Quarter total revenue in the range of $8.7 million to $8.9 million , an increase of approximately 7% sequentially, and 2% over the same period last year. First Quarter core recurring Biologics revenue in the range of $8.55 million to
April 8, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Jimmy Bornheimer , Vice President of Finance, and